title: Bupropion/naltrexone fixed-dose combination for the treatment of obesity.
abstract: The combination of bupropion and naltrexone is one of the most promising new possibilities for the treatment of obesity in an era of increasing prevalence of this disease and decreasing options for its pharmacological management. Although approved by FDA panel members, it was temporally rejected by the FDA afterwards, who demanded more cardiovascular safety data for its commercialization. This monograph will focus on the physiology involved in its mechanisms of action and results of clinical trials.
authors.affiliation: Obesity & Metabolic Syndrome Unit, Division of Endocrinology & Metabolism, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
authors.forename: B
authors.initials: B
authors.lastname: Halpern
authors.forename: A M
authors.initials: AM
authors.lastname: Faria
authors.forename: Alfredo
authors.initials: A
authors.lastname: Halpern
mesh_terms: D000818:Animals; D016642:Bupropion / Q000008:administration & dosage* / Q000494:pharmacology; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D006801:Humans; D009271:Naltrexone / Q000008:administration & dosage* / Q000494:pharmacology; D009765:Obesity / Q000188:drug therapy*
chemical_list: D004338:Drug Combinations; D016642:Bupropion; D009271:Naltrexone